Abstract Session 11

Co-Chair(s)

• 

  Samir Parekh, MD

  Professor of Medicine, Hematology-​Oncology & Oncological Sciences
  Mount Sinai Medical Center, New York, NY, USA
  New Yrok, New York, United States
• 

  Brian Walker, PhD (he/him/his)

  Professor
  Indiana University
  Indianapolis, Indiana, United States

Presentations:

• 11:15 AM – 11:27 AM East Coast USA Time

  OA – 29: Mezigdomide (MEZI), tazemetostat (TAZ), and dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial
  

  Speaker: Luciano J. Costa, MD, PhD – University of Alabama at Birmingham, Birmingham, AL, USA
• 11:27 AM – 11:39 AM East Coast USA Time

  OA – 57: Results of a phase 1 clinical trial of belantamab mafadotin (BelMaf) combined with carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma (MM) after one prior line of therapy (LOT)
  

  Speaker: Shebli Atrash, MD – Levine Cancer Institute
• 11:39 AM – 11:51 AM East Coast USA Time

  OA – 58: Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)
  

  Speaker: Abel Costa, MD – D'Or Institute for Research and Education
• 11:51 AM – 12:03 PM East Coast USA Time

  OA – 61: All oral triplet Iberdomide Ixazomib and Dexamethasone in elderly patients with multiple myeloma patients at first relapse : results of the IFM phase 2 study I2D
  

  Speaker: Cyrille Touzeau, MD, PhD – CHU Nantes
• 12:03 PM – 12:15 PM East Coast USA Time

  OA – 62: Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin, pomalidomide, dexamethasone vs pomalidomide plus bortezomib, dexamethasone (PVd) in relapsed/refractory multiple myeloma
  

  Speaker: Suzanne Trudel, MD – Princess Margaret Cancer Centre, Toronto, ON, Canada